Jasper Therapeutics, Inc. (JSPRW) Stock Price & Analysis

Jasper Therapeutics, Inc. (JSPRW) Healthcare & Pipeline Overview

Jasper Therapeutics, Inc. is a clinical-stage biotechnology firm specializing in advanced therapeutic agents for hematopoietic stem cell transplantation and gene therapies, aiming to transform treatment paradigms through innovative conditioning regimens and engineered cell therapies.

What Is the Investment Thesis for JSPRW?

Jasper Therapeutics, Inc. is poised for growth driven by its innovative product pipeline, particularly the clinical development of briquilimab. The global market for hematopoietic stem cell transplantation is projected to grow significantly, offering substantial revenue potential for Jasper as it advances its therapies through clinical trials. The company's focus on reducing transplant toxicity through targeted therapies positions it well within the biotechnology sector. However, investors should remain cautious of the inherent risks associated with clinical trial outcomes and regulatory approvals, which are critical for the company's success. Monitoring upcoming clinical trial results and potential partnerships will be essential for assessing Jasper's growth trajectory.

Based on FMP financials and quantitative analysis

JSPRW Key Highlights

Market Cap: $0.00B, indicating early-stage development and investment potential.

• Beta: 3.02, reflecting high volatility typical of biotechnology stocks.
• No dividend yield, aligning with the company's focus on reinvestment into research and development.
• 64 employees, showcasing a lean operational structure focused on innovation.
• Lead product briquilimab in clinical trials, targeting significant unmet medical needs.

Who Are JSPRW's Competitors?

JSPRW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are JSPRW's Key Strengths?

Innovative lead product in clinical trials with potential for significant impact.

• Strong focus on addressing unmet medical needs in hematology.
• Expertise in developing specialized therapies and conditioning regimens.
• Agile operational structure enabling rapid adaptation to market changes.

What Are JSPRW's Weaknesses?

Limited financial resources due to early-stage development.

• High dependency on successful clinical trial outcomes.
• No current revenue stream, relying on external funding.
• Small employee base may limit operational capacity.

What Are the Key Risks for JSPRW?

Financial-distress signal — its Altman Z-Score of -49.96 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• High dependency on the success of clinical trials for product candidates.
• Regulatory approval processes that may delay product launches.
• Market volatility affecting funding and investor sentiment.
• Competition from established biotechnology firms with similar product offerings.

What Threats Does JSPRW Face?

• Intense competition from established biotechnology firms.
• Regulatory challenges and uncertainties in the clinical trial process.
• Market volatility affecting funding and investment opportunities.
• Potential changes in healthcare regulations impacting product commercialization.

What Are JSPRW's Competitive Advantages?

• Innovative product pipeline with unique therapies addressing unmet medical needs.
• Expertise in developing specialized conditioning regimens for stem cell transplantation.
• Strong focus on clinical research and development to drive innovation.
• Potential for strategic partnerships enhancing research capabilities and market reach.
• Lean operational structure allowing for agile decision-making and innovation.

What Does JSPRW Do?

Founded in Redwood City, California, Jasper Therapeutics, Inc. is a biotechnology company dedicated to the clinical development of therapeutic agents aimed at hematopoietic stem cell transplantation and gene therapies. The company's strategic focus is on developing and commercializing treatments for various conditions, including chronic spontaneous urticaria and myelodysplastic syndrome. Jasper's innovative approach includes the formulation of novel preparatory treatments, or conditioning regimens, which are critical for successful stem cell transplants and ex-vivo gene therapy. Their lead investigational product, briquilimab, is a therapeutic antibody currently undergoing clinical trials. This product is designed to efficiently clear hematopoietic stem cells from a patient's bone marrow, facilitating the process of receiving an allogeneic stem cell or stem cell gene therapy. Additionally, Jasper Therapeutics is dedicated to engineering specialized hematopoietic stem cell product candidates that address significant limitations often faced with both allogeneic and autologous gene-edited stem cell grafts. With a team of 64 employees, Jasper Therapeutics is positioned to leverage its innovative technologies and clinical insights to make a meaningful impact in the healthcare landscape, particularly in the treatment of hematological disorders.

What Products and Services Does JSPRW Offer?

• Develop therapeutic agents for hematopoietic stem cell transplantation.
• Focus on gene therapies for various hematological conditions.
• Conduct clinical trials to advance lead product briquilimab.
• Engineer specialized hematopoietic stem cell product candidates.
• Create innovative conditioning regimens for stem cell transplants.
• Address critical limitations in existing stem cell therapies.

How Does JSPRW Make Money?

• Revenue generation through the commercialization of therapeutic agents.
• Funding from partnerships and collaborations with larger pharmaceutical companies.
• Potential licensing agreements for proprietary technologies and products.
• Grants and investments aimed at advancing clinical trials and research.
• Future revenue from successful product launches in the biotechnology market.

What Industry Does JSPRW Operate In?

The biotechnology industry is experiencing robust growth, driven by advancements in genetic therapies and an increasing demand for innovative treatments for chronic diseases. The competitive landscape includes several established players, but Jasper's unique approach to conditioning regimens and engineered cell therapies may provide a distinct advantage as the market evolves.

Who Are JSPRW's Key Customers?

• Healthcare providers and hospitals specializing in hematology and oncology.
• Patients requiring hematopoietic stem cell transplantation.
• Research institutions focused on gene therapy and stem cell research.
• Pharmaceutical companies seeking innovative therapies for collaboration.
• Investors interested in biotechnology advancements.

8 transactions · 2 purchases, 0 sales, 6 other transactions · 6 identified insiders · available records within the last 180 days, newest dated Jul 31, 2026 (coverage not recorded). Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Wall Street analysts project Jasper Therapeutics, Inc. revenue of about $12.0M for fiscal 2026, with EPS near $-0.67. The estimate reflects 5 contributing analysts.

Jasper Therapeutics, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 17.6% above estimates on average.

Jasper Therapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -49.96 places it in the distress zone, a signal of elevated financial risk.

Key Financial Metrics

A current ratio of 1.47 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -177.7%, the inverse of the P/E and a quick read on earnings relative to price.

Company Profile

Jasper Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Redwood City, US. The company is led by CEO Jeetinder Singh Mahal. JSPRW has traded publicly since 2026.

JSPRW Financials

JSPRW Latest News

JSPRW Analyst Consensus

JSPRW MoonshotScore

JSPRW Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources